NDA 020411 · Ferring Pharms INC
Cervidil
Dinoprostone · Vaginal · Prostaglandin Analog
Last checked: Nov 20, 2026Latest source record: Jul 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Mar 30, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
144
30 Phase 3, 9 recruiting
FAERS reports
769
660 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 2, 2023.
CERVIDIL is indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor. CERVIDIL is a prostaglandin analog indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor. ( 1 )
Mechanism: Dinoprostone is found in low concentrations in most tissues of the body and functions as a local hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F 2α ( PGF 2α), which sensitizes the myometrium to endogenous or exogenously administered oxytocin. Available evidence indicates that dinoprostone, in the concentrations found during the early part of labor, plays an important role in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 1995 Original approval · Type 3 - New Dosage Form
1 products under this application
- CERVIDIL · DINOPROSTONE 10MG · INSERT, EXTENDED RELEASE, VAGINAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dinoprostone" as an intervention, any sponsor and status, largest first.
- Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2Pivotal-lookingCompleted
University Hospital, ToulouseAcademic, hospital or other
NCT01765881 · 1,700 participants · Start Sep 2012 · Primary completion Sep 2015
Drug: Misoprostol; Dinoprostone · For: Delivery Uterine
Sites: Toulouse, France; Le Kremlin-Bicêtre, France; Poissy, France · 4 sites in all
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical RipeningPivotal-lookingRecruiting
University Hospital, ToursAcademic, hospital or other
NCT04949633 · 1,494 participants (planned) · Start Sep 28, 2021 · Primary completion Sep 2027
Drug: Prostaglandins; Oxytocin · For: Cervical Ripening; Unfavorable Cervix
Sites: Angers, France; Bordeaux, France; Brest, France · 14 sites in all
- Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal DeliveryPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01127581 · 1,358 participants · Start Sep 2010 · Primary completion Mar 2012
Drug: MVI 200; Dinoprostone Vaginal Insert (DVI) · For: Reducing Time to Vaginal Delivery; Cervical Ripening; Induction of Labor
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 34 sites in all
- Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of LaborPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00308711 · 1,308 participants · Start Apr 2006 · Primary completion Aug 2007
Drug: Misoprostol vaginal insert 100 mcg; Misoprostol vaginal insert 50 mcg and 1 more · For: Cervical Ripening; Labor, Induced
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 52 sites in all
- Mechanical cervicAl ripeninG for Women With PrOlongedPregnanciesPivotal-lookingCompleted
University Hospital, ToursAcademic, hospital or other
NCT02907060 · 1,224 participants · Start Jan 27, 2017 · Primary completion Dec 12, 2018
Drug: Pharmacological cervical ripening · For: Prolonged Pregnancy
Sites: Brest, France; Caen, France; Cergy-Pontoise, France · 14 sites in all
Ankara UniversityAcademic, hospital or other
NCT02393144 · 1,000 participants (planned) · Start Feb 2015 · Primary completion Jan 2017
Drug: Analgesics, Opioid, Meperidine; Labor augmentation, Oxytocin and 2 more · For: Pregnancy; Obstetric Labor
Sites: Ankara, Turkey (Türkiye)
- Comparison of Misoprostol and Prostaglandin E2 (PGE2) Gel for Induction of Labour in Premature Rupture of Membranes at TermPivotal-lookingCompleted
Nilratan Sircar Medical CollegeGovernment (non-federal)
NCT00355303 · 932 participants · Start Aug 2006 · Primary completion May 2013
Drug: Misoprostol; PGE2 gel · For: Premature Rupture of Membranes at Term
Sites: Kolkata, India
- The Balloon Project for Birth InductionPivotal-lookingCompleted
Glostrup University Hospital, CopenhagenAcademic, hospital or other
NCT01255839 · 825 participants · Start Dec 2002 · Primary completion Sep 2005
Drug: Minprostin · For: Induction Time; Apgar Score; Admission to Neonatal Unit and 2 more
Sites: Glostrup Municipality, Denmark
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy127
- drug exposure during pregnancy70
- exposure during pregnancy70
- caesarean section63
- maternal exposure during pregnancy58
- premature separation of placenta47
- off label use44
- uterine hyperstimulation41
- drug ineffective36
- premature baby35
- haemoglobin decreased33
- premature delivery33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 8 |
| 2006 | 24 |
| 2007 | 10 |
| 2008 | 29 |
| 2009 | 9 |
| 2010 | 5 |
| 2011 | 18 |
| 2012 | 15 |
| 2013 | 21 |
| 2014 | 13 |
| 2015 | 18 |
| 2016 | 36 |
| 2017 | 50 |
| 2018 | 58 |
| 2019 | 39 |
| 2020 | 46 |
| 2021 | 54 |
| 2022 | 66 |
| 2023 | 95 |
| 2024 | 54 |
| 2025 | 54 |
| 2026 | 38 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-dose oral misoprostol for induction of labour.
Kerr RS, Kumar N, Williams MJ, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Oral misoprostol for induction of labour.
Alfirevic Z, Aflaifel N, Weeks A · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Propess versus prostin for induction of labour in term primiparous women.
Hung CH, Chen HY, Kang J, et al. · J Formos Med Assoc 2023 · Randomized Controlled Trial
- Optimising daytime deliveries when inducing labour using prostaglandin vaginal inserts.
Miller H, Goetzl L, Wing DA, et al. · J Matern Fetal Neonatal Med 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Prostaglandin E2 for cervical ripening: a randomized comparison of Cervidil versus Prepidil.
Chyu JK, Strassner HT · Am J Obstet Gynecol 1997 · Clinical Trial, Comparative Study
- Methods of induction of labour: a network meta-analysis.
Rattanakanokchai S, Gallos ID, Kietpeerakool C, et al. · Cochrane Database Syst Rev 2026 · Network Meta-Analysis
Sponsor: Ferring Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.